BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 12680175)

  • 1. Estrogen and progesterone receptor expression in patients with uterine leiomyosarcoma and correlation with different clinicopathological parameters.
    Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Leodolter S; Mayerhofer K
    Anticancer Res; 2003; 23(1B):729-32. PubMed ID: 12680175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The expression of Ki-67, p53, estrogen and progesterone receptors affecting survival in uterine leiomyosarcomas. A clinicopathologic study.
    Akhan SE; Yavuz E; Tecer A; Iyibozkurt CA; Topuz S; Tuzlali S; Bengisu E; Berkman S
    Gynecol Oncol; 2005 Oct; 99(1):36-42. PubMed ID: 15992918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma.
    Leitao MM; Soslow RA; Nonaka D; Olshen AB; Aghajanian C; Sabbatini P; Dupont J; Hensley M; Sonoda Y; Barakat RR; Anderson S
    Cancer; 2004 Sep; 101(6):1455-62. PubMed ID: 15316901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oestrogen and progesterone receptor expression in patients with adenocarcinoma of the uterine cervix and correlation with various clinicopathological parameters.
    Bodner K; Laubichler P; Kimberger O; Czerwenka K; Zeillinger R; Bodner-Adler B
    Anticancer Res; 2010 Apr; 30(4):1341-5. PubMed ID: 20530450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical expression of estrogen and progesterone receptors and outcomes in patients with newly diagnosed uterine leiomyosarcoma.
    Leitao MM; Hensley ML; Barakat RR; Aghajanian C; Gardner GJ; Jewell EL; O'Cearbhaill R; Soslow RA
    Gynecol Oncol; 2012 Mar; 124(3):558-62. PubMed ID: 22085894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bcl-2 receptor expression in patients with uterine smooth muscle tumors: an immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
    Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K
    J Soc Gynecol Investig; 2004 Apr; 11(3):187-91. PubMed ID: 15051039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of thrombospondin 1 (TSP 1) in patients with uterine smooth muscle tumors: an immunohistochemical study.
    Bodner-Adler B; Nather A; Bodner K; Czerwenka K; Kimberger O; Leodolter S; Mayerhofer K
    Gynecol Oncol; 2006 Oct; 103(1):186-9. PubMed ID: 16595146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estrogen and progesterone receptor expression in patients with uterine smooth muscle tumors.
    Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K
    Fertil Steril; 2004 Apr; 81(4):1062-6. PubMed ID: 15066464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating prognostic parameters in women with uterine leiomyosarcoma. A clinicopathologic study.
    Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Leodolter S; Mayerhofer K
    J Reprod Med; 2003 Feb; 48(2):95-100. PubMed ID: 12621792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis.
    Bodner-Adler B; Bodner K; Czerwenka K; Kimberger O; Leodolter S; Mayerhofer K
    Gynecol Oncol; 2005 Jan; 96(1):62-6. PubMed ID: 15589581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
    Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
    Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors and impact of adjuvant chemotherapy for uterine leiomyosarcoma.
    Wu TI; Chang TC; Hsueh S; Hsu KH; Chou HH; Huang HJ; Lai CH
    Gynecol Oncol; 2006 Jan; 100(1):166-72. PubMed ID: 16182349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leiomyosarcoma of the uterus: a clinicopathologic multicenter study of 71 cases.
    Mayerhofer K; Obermair A; Windbichler G; Petru E; Kaider A; Hefler L; Czerwenka K; Leodolter S; Kainz C
    Gynecol Oncol; 1999 Aug; 74(2):196-201. PubMed ID: 10419731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
    Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
    Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical characteristics and prognosis of breast cancer patients with vascular invasion].
    Zhao WH; Xu BH; Zhang P; Li Q; Zhao LM; Sun Y
    Zhonghua Zhong Liu Za Zhi; 2007 Feb; 29(2):137-40. PubMed ID: 17645853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of matrix metalloproteinases in patients with uterine smooth muscle tumors: an immunohistochemical analysis of MMP-1 and MMP-2 protein expression in leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
    Bodner-Adler B; Bodner K; Kimberger O; Czerwenka K; Leodolter S; Mayerhofer K
    J Soc Gynecol Investig; 2004 Apr; 11(3):182-6. PubMed ID: 15051038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tamoxifen-associated malignant endometrial tumors: pathologic features and expression of hormone receptors estrogen-alpha, estrogen-beta and progesterone; a case controlled study.
    Wilder JL; Shajahan S; Khattar NH; Wilder DM; Yin J; Rushing RS; Beaven R; Kaetzel C; Ueland FR; van Nagell JR; Kryscio RJ; Lele SM
    Gynecol Oncol; 2004 Feb; 92(2):553-8. PubMed ID: 14766247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of estrogen receptor and progesterone receptor status in young Chinese ovarian carcinoma patients.
    Yang XY; Xi MR; Yang KX; Yu H
    Gynecol Oncol; 2009 Apr; 113(1):99-104. PubMed ID: 19178934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer.
    Jongen V; Briƫt J; de Jong R; ten Hoor K; Boezen M; van der Zee A; Nijman H; Hollema H
    Gynecol Oncol; 2009 Mar; 112(3):537-42. PubMed ID: 19108875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.